 |
|
|
| |
Treatment with the 2nd generation HCV protease inhibitor BI 201335 results in high and consistent SVR rates - results from SILEN-C1 in treatment-naïve patients across different baseline factors
|
| |
| |
Reported by Jules Levin
AASLD Nov 5-9 2011 SF
M.S. Sulkowski,1 T. Asselah,2 P. Ferenci,3
J.O. Stern,4 G. Kukolj,5 W. Bocher,6 J. Scherer4
On behalf of the SILEN-C1 study group
1Johns Hopkins University, Baltimore, MD, USA; 2Hopital Beaujon, Clichy Cedex, France; 3Medical University of Vienna, Vienna, Austria; 4Boehringer Ingelheim, Ridgefield, CT, USA; 5Boehringer Ingelheim (Canada) Ltd; 6Boehringer Ingelheim Pharma, GmbH, Biberach, Germany
|
| |
|
|
|
|
|
